Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

All Oncology News

Gymnastics Makes Me a Better Oncologist

September 2nd 2021

Valentina Baez Sosa, MD

Valentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.

Evolving Treatment Approaches Pre- and Post-Transplant

September 2nd 2021

Harry P. Erba, MD, PhD, Duke Cancer Institute

Vinod Pullarkat, MD, leads a detailed discussion on evolving treatment approaches using MRD pretransplant, and panelists consider recent therapeutic advances for the post-transplant setting.

5-Year Follow-up Data on CPX-351 for AML

September 2nd 2021

Harry P. Erba, MD, PhD, Duke Cancer Institute

A panel of specialists in hematology oncology review the 5-year follow-up data on the use of CPX-351 for adults and pediatric patients with acute myeloid leukemia.

PACIFIC Led to Subtle but Swift Adoption of Concurrent Chemoradiation and Durvalumab in Stage III NSCLC

September 2nd 2021

Caroline Seymour

An increase in the use of concurrent chemoradiation followed by durvalumab was found in patients with stage III non–small cell lung cancer who were treated at 3 Dutch centers in The Netherlands between 2015 and 2019.

Limitations When Managing Chemo-Induced Myelosuppression

September 2nd 2021

Charu Aggarwal, MD

Pros and cons of strategies used to manage chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer.

Guidelines for Managing Chemo-Induced Myelosuppression in ES-SCLC

September 2nd 2021

Charu Aggarwal, MD, MPH, University of Pennsylvania Hospital

Guidance for managing chemotherapy-induced myelosuppressive events in patients with extensive-stage small cell lung cancer based on risk stratification criteria, available therapies, and prophylaxis options.

FDA Approves Zanubrutinib in Waldenström Macroglobulinemia

September 1st 2021

Caroline Seymour

The FDA has approved zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Dr. Hurvitz on Outcomes With Sacituzumab Govitecan in TNBC

September 1st 2021

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.

Dr. Garg on the Need for Novel Imaging Techniques in nmCRPC

September 1st 2021

Natasha Garg, DO

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wang on the Final Results of the ACE-LY-004 Trial in MCL

September 1st 2021

Michael Wang, MD

Michael Wang, MD, discusses the use of acalabrutinib in the phase 2 ACE-LY-004 trial in mantle cell lymphoma.

Dr. Stevenson on the Importance of Early Screening in Lung Cancer

September 1st 2021

James Stevenson, MD

James Stevenson, MD, discusses the importance of early screening in lung cancer.

Dr. Riedell on the Importance of Identifying Early Relapse High-Risk MCL

September 1st 2021

Peter Riedell

Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.

Rolling Submission of BLA to FDA Completed for Toripalimab Plus Chemotherapy in Metastatic Nasopharyngeal Carcinoma

September 1st 2021

Courtney Marabella

The rolling submission of a biologics license application to support the approval of both toripalimab plus gemcitabine- and cisplatin-based chemotherapy as a first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, as well as toripalimab monotherapy for the second-line or beyond treatment of patients with recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy has been completed.

Emerging Options Open the Door to Optimized Treatment Opportunities in Hematologic Malignancies

September 1st 2021

Jessica Hergert

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma

September 1st 2021

Courtney Marabella

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

See All News